-
近半个世纪以来,国内外学者对肿瘤研究给予了极大的关注,并对肿瘤的发生、发展机制进行了深入研究并取得了重要进展[1-2]。尽管如此,在全世界范围内恶性肿瘤发病率及病死率仍然呈上升趋势,极大地危害着人类的生命健康。人类面临防治恶性肿瘤的巨大挑战。
虽然研究人员在基础研究领域对癌变机制的研究不断深入并取得了巨大成果[3-4],然而在临床工作中恶性肿瘤的诊断及治疗进展却十分缓慢。多数患者发现病变时已属中晚期,分子影像学的出现则弥补了传统诊断的局限性,一定程度上满足医学发展的需求。其在形态解剖的基础上,更多地反映组织细胞的生物学信息,如增殖、代谢、新生血管形成、基因表达等[5-6]。其中,核医学核素示踪分子功能显像采用的分子探针或示踪剂通过不同机制与肿瘤组织靶向结合,实现了分子水平上的真正生物活体显像,并且在疑难病例的诊治方面正逐渐发挥更大作用[7-8]。
核素示踪靶向肿瘤新生血管分子探针的研究进展
Progress and prospect of molecular probes of radionuclide tracing targeted tumor angiogenesis
-
摘要: 肿瘤是一种严重危害人类健康和生命的疾病,它的早期诊断和早期治疗可以明显延长患者的生存时间和提高患者的生活质量。目前,肿瘤靶向诊断和靶向治疗成为研究热点。靶向肿瘤新生血管的多肽精氨酸-精氨酸-亮氨酸(RRL)序列能够特异性靶向结合于肿瘤来源内皮细胞,国内学者证实了131I-RRL对肿瘤细胞的杀伤作用,以及99Tcm-RRL在不同肿瘤模型中的SPECT显像效果。国外学者已经将靶向肿瘤新生血管的小分子多肽精氨酸-甘氨酸-天冬氨酸用于临床前期阶段。
-
关键词:
- 肿瘤新生血管 /
- 异质性 /
- 早期诊断 /
- 个性化治疗 /
- 精氨酸-精氨酸-亮氨酸
Abstract: Tumor is hazard to human health and lives. Early diagnosis and treatment of tumor can obviously prolong patient survival time and improve the quality of life. At present, targeting diagnosis and therapy catch attention of researchers from all over the world. Peptide arginine-arginine-leucine(RRL)sequence is specific targeted to tumor-derived endothelial cell. Our team confirmed that the 131I-RRL had the effect of killing tumor cells, and 99Tcm-RRL could image tumors in different tumor models. Foreign scholars have already put the small molecules arginine-arginine-leucine targeting tumor angiogenesis in the preclinical stage. -
[1] Liu H, Bao D, Xia X, et al. An unconventional role of BMP-Smad1 signaling in DNA damage response:a mechanism for tumor suppression[J]. J Cell Biochem, 2014, 115(3):450-456. doi: 10.1002/jcb.24698 [2] 徐小雯, 傅传刚.抗血管生成药物改善肿瘤血供及含氧量的机制探讨和应用展望[J].中华胃肠外科杂志, 2014, 17(11):1148-1150. doi: 10.3760/cma.j.issn.1671-0274.2014.11.23
[3] Wong MM, Guo C, Zhang J. Nuclear receptor corepressor complexes in cancer:mechanism, function and regulation[J]. Am J Clin Exp Urol, 2014, 2(3):169-187. [4] Rubin MA. Insights into the mechanism of organ-specific cancer metastasis[J]. Cancer Discov, 2014, 4(11):1262-1264. doi: 10.1158/2159-8290.CD-14-1075 [5] Lee J, Lee TS, Ryu J, et al. RGD peptide-conjugated multimodal NaGdF4:Yb3+/Er3+ nanophosphors for upconversion luminescence, Mr, and PET imaging of tumor angiogenesis[J]. J Nucl Med, 2013, 54(1):96-103. [6] Kang L, Wang RF, Yan P, et al. Noninvasive visualization of RNA delivery with 99mTc-radiolabeled small-interference RNA in tumor xenografts[J]. J Nucl Med, 2010, 51(6):978-986. [7] 王荣福.分子核医学应用研究进展[J].中国临床医学影像杂志, 2008, 19(8):585-590. doi: 10.3969/j.issn.1008-1062.2008.08.015
[8] 王荣福.核医学[M]. 3版.北京: 北京大学医学出版社, 2013.
[9] Liu M, Wang RF, Zhang CL, et al. Noninvasive imaging of human telomerase reverse transcriptase(hTERT)messenger RNA with 99mTc-radiolabeled antisense probes in malignant tumors[J]. J Nucl Med, 2007, 48(12):2028-2036. doi: 10.2967/jnumed.107.042622 [10] 王荣福.肿瘤分子功能显像诊断与靶向治疗[J].肿瘤学杂志, 2010, 16(6):421-422.
[11] Roessler S, Budhu A, Wang XW. Deciphering cancer heterogeneity:the biological space[J]. Front cell dev biol, 2014, 2:12. [12] 王荣福.核素示踪技术在疾病诊治中的应用[J].肿瘤学杂志, 2013, 19(12):911-913.
[13] Yu Y, He J. Molecular classification of non-small-cell lung cancer:diagnosis, individualized treatment, and prognosis[J]. Front Med, 2013, 7(2):157-171. [14] 王荣福. PET/CT-分子影像学新技术应用[M].北京: 北京大学医学出版社, 2011.
[15] 王荣福. PET/CT新技术应用[J]. CT理论与应用研究, 2009, 18(4):9-14.
[16] Price P, Jones T. Can positron emission tomography(PET)be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group[J]. Eur J Cancer, 1995, 31A(12):1924-1927. [17] 王荣福. PET/CT肿瘤诊断学[M].北京: 北京大学医学出版社, 2008.
[18] 王金娥, 陈刚. 18F-FDG PET/CT对淋巴瘤化疗疗效的评估[J].肿瘤学, 2014, 20(11):898-904.
[19] 王荣福.核医学分子功能成像和靶向治疗在淋巴瘤中临床应用进展[J].肿瘤学杂志, 2009, 15(9):861-865.
[20] Sulakhe D, Balasubramanian S, Xie B, et al. High-throughput translational medicine:challenges and solution[J]. Adv Exp Med Biol, 2014, 799(1):39-67. [21] Lu X, Wang RF. A concise review of current radiopharmaceuticals in tumor angiogenesis imaging[J]. Curr Pharm Des, 2012, 18(8):1032-1040. doi: 10.2174/138161212799315812 [22] Brown CK, Modzelewski RA, Johnson CS, et al. A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli Peptide Display Library[J]. Ann Surg Oncol, 2000, 7(10):743-749. doi: 10.1007/s10434-000-0743-0 [23] Weller GE, Wong MK, Modzelewski RA, et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine[J]. Cancer Res, 2005, 65(2):533-539. [24] 刘红洁, 王荣福, 张春丽, 等. 131Ⅰ标记RGD环肽在荷瘤小鼠体内分布与显像研究[J].中国医学影像技术, 2008, 24(1):131-133. doi: 10.3321/j.issn:1003-3289.2008.01.038
[25] Yu MM, Wang RF, Yan P, et al. Design, synthesis and iodination of an Arg-Arg-Leu peptide for potential use as an imaging agent for human prostate carcinoma[J]. J Labelled Comp Radiopharm, 2008, 51(11/12):374-378. [26] 王荣福, 于明明, 闫平, 等.碘标记肿瘤血管靶向多肽研究[J].同位素杂志, 2009, 22(2):96-100.
[27] Lu X, Yan P, Wang RF, et al. The further study on radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging[J/OL]. J Radioanal Nucl Chemistry, 2011, 290(3): 623-630[2014-12-20]. http://link.springer.com/article/10.1007%2FS10967-011-1342-1. [28] 于明明, 王荣福, 张春丽, 等. 131I标记精氨酸-精氨酸-亮氨酸多肽在荷瘤小鼠体内的分布与显像[J].中国医学影像技术, 2009, 25(1):10-14. doi: 10.3321/j.issn:1003-3289.2009.01.004
[29] Yu M, Zhou H, Liu X, et al. Study on biodistribution and imaging of radioiodinated arginine-arginine-leucine peptide in nude mice bearing human prostate carcinoma[J]. Ann Nucl Med, 2010, 24(1):13-19. [30] Lu X, Yan P, Wang RF, et al. Use of radioiodinated peptide Arg-Arg-Leu targeted to neovasculari- zation as well as tumor cells in molecular tumor imaging[J]. Chin J Cancer Res, 2012, 24(1):52-59. doi: 10.1007/s11670-012-0052-8 [31] Zhao Q, Yan P, Yin L, et al. Validation study of 131I-RRL:assessment of biodistribution, SPECT imaging and radiation dosimetry in mice[J]. Mol Med Rep, 2013, 7(4):1355-1360. doi: 10.3892/mmr.2013.1338 [32] Zhao Q, Yan P, Wang RF, et al. A novel 99mTc-labeled molecular probe for tumor angiogenesis imaging in hepatoma xenografts model: a pilot study[J/OL]. PLoS One, 2013, 8(4): e61043[2014-12-20].http://journals. plos. org/plosone/article?id=10. 1371/journal. pone. 0061043. [33] 崔永刚, 张春丽, 王荣福, 等. 131I标记cRGD环肽对荷黑色素瘤小鼠靶向治疗作用[J].中华核医学杂志, 2009, 29(2):92-95. doi: 10.3760/cma.j.issn.0253-9780.2009.02.006
[34] 张春丽, 王荣福, 张丽, 等.靶向整合素αvβ3受体的二硫键成环的RGD肽的设计、131I标记及在荷瘤鼠中的生物分布与显像[J].肿瘤学杂志, 2010, 16(4):276-280. doi: 10.3760/cma.j.issn.1673-422X.2010.04.012
[35] 刘红洁, 王荣福, 张春丽. RGD肽在肿瘤显像和治疗中的应用研究进展[J].肿瘤学杂志, 2008, 14(8):620-622.
[36] 张丽, 张春丽, 王荣福, 等. RGD多肽类药物设计、活性测定及99Tcm-cRGD二聚体的制备[J].核化学与放射化学, 2011, 33(2):106-113.
[37] 张春丽, 王荣福, 张丽, 等.靶向整合素αvβ3受体的新型RGD肽二聚体的~131I标记与生物活性的初步评价[J].北京大学学报:医学版, 2011, 43(2):295-300.
[38] 李玲, 张春丽, 王荣福.整合素αvβ3非肽类小分子拮抗剂的设计及其在肿瘤显像中的研究进展[J].同位素, 2010, 23(4):247-252.
[39] Shastry BS. Phamacogenetics and the concept of individualized medicine[J]. Phamacogenomics J, 2006, 6(1):16-21. [40] Mcdermott U, Pusapati R V, Christensen J G, et al. Acquired resistance of non-small cell lung cancer cells to Met kinase inhibition is mediated by a Switch to epidermal growth factor receptor dependency[J]. Cancer Res, 2010, 70(4):1625-1634. [41] 钟南山.中国临床医生转化医学实践之路[J].中国实用内科杂志, 2012, 32(7):481-483.
[42] 崔志文, 夏烨, 孙小娟, 等.国内外转化医学发展历程与展望[J].生命科学, 2012, 24(4):316-320.
[43] 付小兵.中国的再生医学研究:需求与转化应用[J].解放军医学杂志, 2012, 37(3):169-171.
[44] 王荣福.核医学分子靶向诊断与治疗[J].肿瘤学杂志, 2014, 20(11):871-874. doi: 10.11735/j.issn.1671-170X.2014.11.B001
[45] Yao N, Chen XQ, Wang RF. Application progress of nano-material in molecule functional imaging with radionuclide tracing technique and targeted treatment[J]. J Mol Biol Techniques, 2014, 1(1):1-5. [46] Zhu ZH, Miao WB, Li QW, et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer:a multicenter study[J]. J Nucl Med, 2012, 53(5):716-722. [47] Shi J, Fan D, Dong C, et al. Anti-tumor effect of integrin targeted177Lu-3PRGD2 and combined therapy with Endostar[J]. Theranostics, 2014, 4(3):256-266. doi: 10.7150/thno.7781
计量
- 文章访问数: 3913
- HTML全文浏览量: 2672
- PDF下载量: 3